SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-20-009546
Filing Date
2020-05-20
Accepted
2020-05-20 16:53:50
Documents
56
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 1093956
2 ex31-1.htm EX-31.1 18486
3 ex31-2.htm EX-31.2 18421
4 ex32-1.htm EX-32.1 7902
5 ex32-2.htm EX-32.2 7824
  Complete submission text file 0001493152-20-009546.txt   4947914

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE rspi-20200331.xml EX-101.INS 877084
7 XBRL SCHEMA FILE rspi-20200331.xsd EX-101.SCH 82355
8 XBRL CALCULATION FILE rspi-20200331_cal.xml EX-101.CAL 38668
9 XBRL DEFINITION FILE rspi-20200331_def.xml EX-101.DEF 214431
10 XBRL LABEL FILE rspi-20200331_lab.xml EX-101.LAB 441622
11 XBRL PRESENTATION FILE rspi-20200331_pre.xml EX-101.PRE 281141
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-16467 | Film No.: 20898793
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences